HALO (Halozyme Therapeutics) Forward P/E Multiple

Official company branding of Halozyme (HALO)

Halozyme Therapeutics (HALO) possesses a colossal liquidity reserve thanks to a low-cost royalty collection model. Business revenues are independent of economic cycles or seasonality, demonstrating resilience to shocks. The environmental focus is directed toward reducing medical waste. The trend of the company's forward P/E reflects a shift in market valuations, and the value of 9.40 shows the current magnitude of this indicator.

Halozyme - HALO Forward P/E Multiple (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for Halozyme Therapeutics (HALO)

- current price and projected stock value:
Fundamental valuation:Halozyme Therapeutics, Inc.
Brand item of Halozyme Corp

Forward P/E measures the current stock price relative to expected earnings for the following year. Analyzing the consensus forward P/E of a company allows investors to filter out market noise, revealing the actual overvaluation or undervaluation of assets. This chart reflects the market's confidence in future cash flows. For Halozyme Therapeutics (HALO), this indicator confirms the resilience of the ENHANZE technology licensing model. Stable royalties from pharma behemoths make earnings forecasts predictable, thereby reducing investment risks.

Analysis of competing companies

Forward P/E Multiple ONC|RVMD (RevMed) - Future Price to Earnings Multiple|Forward P/E Multiple AAPG (ascentage.com)|CGON - Projected Price to Earnings|URGN: Projected Price to Earnings|BCAX - Forward P/E Multiple|Personalis Corp (PSNL) - Future Price to Earnings|Erasca Corp - Future Price to Earnings Multiple|DCTH (Delcath Systems Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Y-mAbs Therapeutics, Inc. YMAB|Forward P/E Multiple AURA|Projected Price to Earnings Candel Therapeutics, Inc. CADL|Forward P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Future Price to Earnings|ACTU: Projected Price to Earnings|Citius Oncology, Inc. - Market Cap to Future Earnings Ratio|HURA (TuHURA Biosciences) - Projected Price to Earnings|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple